financetom
WYNN
financetom
/
Consumer Discretionary
/
WYNN
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Wynn Resorts, LimitedWYNN
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Wynn Resorts, Limited designs, develops, and operates integrated resorts.

The company operates through four segments: Wynn Palace, Wynn Macau, Las Vegas Operations, and Encore Boston Harbor.

The Wynn Palace segment operates private gaming salons and sky casinos; a luxury hotel tower with suites, and villas, including a health club, spa, salon, and pool; food and beverage outlets; retail space; meeting and convention space; and performance lake and floral art displays.

The Wynn Macau segment operates casino space with private gaming salons, sky casinos, and a poker room; a luxury hotel tower, that include health clubs, spas, a salon, and a pool; food and beverage outlets; retail space; meeting and convention space; and Chinese zodiac-inspired ceiling attractions.

The Las Vegas Operations segment operates casino space with private gaming salons, a sky casino, a poker room, and a race and sports book; a luxury hotel tower with suites, and villas, including swimming pools, private cabanas, full-service spas and salons, and a wedding chapel; food and beverage outlets; meeting and convention space; retail space; and theaters, nightclubs, a beach club.

The Encore Boston Harbor segment operates casino space with gaming areas, and a poker room; a luxury hotel tower including a spa and salon; food and beverage outlets and a nightclub; retail space; meeting and convention space; and a waterfront park, floral displays, and water shuttle service.

Wynn Resorts, Limited was founded in 2002 and is based in Las Vegas, Nevada.

Latest News >
ALX Oncology Q3 net loss narrows as R&D costs drop
ALX Oncology Q3 net loss narrows as R&D costs drop
Nov 7, 2025
Overview * ALX Oncology ( ALXO ) Q3 net loss narrows to $22.1 mln, driven by reduced R&D expenses * Appointed Barbara Klencke, M.D., as interim Chief Medical Officer Outlook * Company expects cash runway to last into Q1 2027 * ALX Oncology anticipates interim data for ASPEN-09 in Q3 2026 * Initial safety data for ALX2004 expected in 1H...
Form 8.3
Form 8.3
Nov 7, 2025
LONDON--(BUSINESS WIRE)--   Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed,...
Novo Nordisk expects negative low single-digit impact on global sales growth in 2026 (Nov 6)
Novo Nordisk expects negative low single-digit impact on global sales growth in 2026 (Nov 6)
Nov 7, 2025
Nov 6 (Reuters) - Novo Nordisk said it currently expects an estimated negative low single-digit impact to global sales growth in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight-loss drugs for U.S. government-backed insurance programs and cash payers. ...
Novo Nordisk expects negative low single-digit impact on global sales growth in 2026 (Nov 6)
Novo Nordisk expects negative low single-digit impact on global sales growth in 2026 (Nov 6)
Nov 7, 2025
(Corrects November 6 story to say Novo expects an estimated negative low single-digit impact, not global sales to decline by low single-digit percentage) (Reuters) -Novo Nordisk said it currently expects an estimated negative low single-digit impact to global sales growth in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight-loss drugs for U.S....
Copyright 2023-2026 - www.financetom.com All Rights Reserved